Grünenthal Acquires Kyowa Kirin’s 49% Stake in Grünenthal Meds JV

Grünenthal Acquires Valinor Pharma for Approximately $250M

July 22, 2024

Pharmaceuticals

Grünenthal has acquired Chicago-based Valinor Pharma, including global rights to Movantik (naloxegol), in a transaction valued at about $250 million. The deal strengthens Grünenthal's U.S. footprint and adds an established pain-management product to its portfolio after Valinor scaled Movantik sales using Apollo Care's commercial and patient-access solutions.

Kyowa Kirin Acquires Orchard Therapeutics

October 5, 2023

Biotechnology

Kyowa Kirin Co., Ltd. agreed to acquire Orchard Therapeutics plc for $16.00 per ADS in cash plus a $1.00 contingent value right (CVR), representing a potential total equity value of approximately $477.6 million. The acquisition gives Kyowa Kirin a leading HSC gene therapy platform and commercial asset Libmeldy, accelerating development and commercialization of Orchard's rare-disease gene therapies.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Chugai Pharmaceutical to Acquire Renalys Pharma

October 24, 2025

Biotechnology

Chugai Pharmaceutical Co., Ltd. will acquire Renalys Pharma, Inc. through a definitive stock purchase agreement. The transaction includes an upfront payment of JPY 15.0 billion and potential earn-outs of up to JPY 16.0 billion tied to regulatory and sales milestones for sparsentan in Japan, South Korea, and Taiwan.

GTCR Acquires Zentiva from Advent

September 11, 2025

Pharmaceuticals

Advent and GTCR announced the sale of Zentiva, a leading European generics pharmaceutical company, with Advent selling Zentiva to GTCR. The transaction is subject to regulatory approvals and is expected to close in early 2026.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.